Street Calls of the Week
Repligen Corporation (NASDAQ:RGEN), a $6.8 billion biotech company with an "GOOD" financial health rating according to InvestingPro, announced the appointment of Violetta Hughes as chief accounting officer, effective September 1, 2025. According to a press release statement based on a recent SEC filing, Hughes will serve as the company’s principal accounting officer, succeeding Jason K. Garland. Garland will continue as chief financial officer, shifting his focus to corporate strategy, financial planning and analysis, capital markets, and growth initiatives.
Hughes, 53, has over 25 years of experience in finance roles across the life sciences, medical technology, and pharmaceutical industries. Prior to joining Repligen, she was vice president and chief accounting officer at Azenta, Inc. (NASDAQ:AZTA) from January 2023 to August 2025. Before that, she held senior finance positions at Akebia Therapeutics, Inc. (NASDAQ:AKBA) and AMAG Pharmaceuticals, Inc. (formerly NASDAQ:AMAG).
Repligen stated that Hughes holds a Bachelor of Science in Accounting from the University of Massachusetts Lowell.
In connection with her appointment, the company’s compensation committee approved an annual base salary of $395,000 for Hughes, along with a one-time signing bonus of $150,000. She will also be eligible for a target annual performance bonus of up to 50% of her base salary. The offer includes an annual equity award totaling $750,000, with $500,000 in restricted stock units and $250,000 in stock options, vesting equally over five years, subject to continued employment. Hughes will be eligible to participate in the company’s employee benefit plans.
Repligen reported that there are no family relationships or related party transactions between Hughes and any executive officer or director of the company, and no arrangements with any other person regarding her selection as an officer.
Repligen Corporation is incorporated in Delaware and its common stock is listed on the Nasdaq Global Select Market under the symbol RGEN. The information in this article is based on a press release statement and the company’s SEC filing.
In other recent news, Repligen Corporation reported its second-quarter earnings for 2025, with revenue surpassing expectations at $182 million compared to the forecasted $175.35 million. Although earnings per share came in slightly lower than anticipated at $0.37, missing the forecast of $0.39, the revenue surprise reflects a positive performance. Additionally, Repligen has entered into a strategic partnership with Austria-based Novasign to integrate machine learning and modeling workflows into its filtration systems. This collaboration includes an investment in Novasign to scale its operations, focusing on enhancing Repligen’s tangential flow filtration systems. In terms of analyst insights, KeyBanc has reiterated an Overweight rating on Repligen, emphasizing strong growth in the biological production market. The firm suggests that the bioprocessing market’s resurgence in double-digit growth could drive mid-teens growth for Repligen. These developments highlight the company’s ongoing efforts to enhance its product offerings and capitalize on market opportunities.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.